# Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis

> **NCT04777539** · — · COMPLETED · sponsor: **Nantes University Hospital** · enrollment: 295 (actual)

## Conditions studied

- Multiple Sclerosis (MS)

## Interventions

- **OTHER:** At-home natalizumab treated MS patient

## Key facts

- **NCT ID:** NCT04777539
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-14
- **Primary completion:** 2024-11-14
- **Final completion:** 2025-05-14
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04777539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04777539, "Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT04777539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*